In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Big Pharma Presence In Gene Therapy Dealmaking Validates Technology

Executive Summary

For several years, smaller biotechs have been advancing gene therapies and delivery technology. Big Pharma companies have increasingly been becoming involved through deal-making, and are ready to take gene therapy to the next level.

You may also be interested in...



Partnering In Cell And Gene Therapy Is A Unique Endeavor

Industry and academic representatives shared viewpoints at Biotech Week Boston in September 2018, including what is unique about deal-making in the cell and gene field.

Cellectis Moves First Off-The-Shelf CAR-T Into US Clinical Trials

UCART123 is behind the initial wave of CAR-T drugs for cancer but could have a big advantage as an allogeneic, or off-the-shelf, option. A Phase I trial is now under way in patients with acute myeloid leukemia.

The Biopharma A List: Taking The Pulse Of Newco Creation

The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV005308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel